This study is being done to test whether adding two drugs-disulfiram and copper gluconate-to radiation therapy can help overcome this resistance and improve treatment outcomes. When disulfiram is combined with copper, it forms a substance that may increase stress within cancer cells and lead to a specific type of cancer cell death knowns as "cuproptosis".
Histologically confirmed locally advanced or metastatic disease of any histology that will receive chest radiation
Scheduled to receive RT as part of definitive local consolidation therapy (LCT) (not palliative)
Induction systemic therapy allowed, but just not concurrently given (washout for at least 3 weeks before start of CDT and RT)
Age ≥18 years.
Uncontrolled intercurrent illness.
Known hypersensitivity to Disulfiram.
Contraindications to radiation therapy.
Inability to stay away from alcohol products during the use of Disulfiram.
Single group
Disulfiram 250 mg
DrugGiven orally once daily
Copper Gluconate 2 mg
DrugGiven orally three times daily
Radiation Therapy
DrugDelivered per institutional standards (radiotherapy alone in 10-15 fractions as local consolidation therapy).
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
